Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644016 · ClinicalTrials.gov registry record · Phase 2
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
A Phase 2 study of AML and MDS, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04644016 is a Phase 2 study of AML and MDS that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants, below the 132-participant average among 29 other AML trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04644016, a Phase 2 study of AML and MDS, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Mycophenolate Mofetil
- DRUG Clofarabine
- DRUG Cyclosporine-A
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2026-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04644016
The ClinicalTrials.gov registry entry for NCT04644016 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 29 other AML trials with a reported enrollment target (77% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with AML appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT04644016 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04644016 about?
NCT04644016 is a clinical study titled "Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders". This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
What is the current status of trial NCT04644016?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-11-20. Estimated completion is 2026-12-20.
What conditions does trial NCT04644016 study?
This clinical trial studies the following conditions: AML, MDS, Hemoglobinopathies, ALL, Bone Marrow Failure.
What interventions are being tested in trial NCT04644016?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Mycophenolate Mofetil (DRUG), Clofarabine (DRUG), Cyclosporine-A (DRUG).
Who is sponsoring clinical trial NCT04644016?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04644016 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
-
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
RECRUITING · Phase 2
-
Cardioprotection in AML
RECRUITING · Phase 2
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
-
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.